April 6, 2021
Xcenda and FormularyDecisions supports AMCP 2021 virtual
AMCP 2021 Networking Session: Managed Care Hot Topic
Xcenda’s Laurie Fazio and Tasmina Hydery will be attending this networking session where the AMCP Format Executive Committee will discuss the latest on Format 4.1 and eDossier.
Since 2000, the AMCP Format for Formulary Submissions has served as the gold standard for providing industry with guidance on the communication of medical product information to healthcare decision makers for the purpose of formulary, coverage, and reimbursement decision making. Version 4.1 provides new guidance on the two-way communication between industry and payers regarding evidence and information about unapproved products and unapproved uses of approved products for which FDA approval is being sought. The new guidance represents a substantial step forward in meeting the evidentiary and informational needs of payers well before FDA approval. Join us for a review and discussion of the Format Executive Committee’s most recent updates to the AMCP Format and eDossiers.
Live FormularyDecisions Demo
Enhance your formulary decision-making process with FormularyDecisions
- Tuesday, April 13 – 12:30-1:00 PM ET
- Wednesday, April 14 – 12:30-1:00 PM ET
Xcenda Continues Excellence in Innovative Research
Join us at the AMCP 2021 virtual conference as we are proud to present the following award-winning research at AMCP. Meet our managed markets and commercialization experts at our virtual booth.
|Gold||Evaluation of payer-initiated oncology clinical pathways: utilization trends, development, and barriers to implementation.||Annie Yan, Seth Cook|
|Bronze||Are US Payers Getting to Grips with Cost-Effectiveness Analysis?||Jackie Gladman, Janet Hughes, Michell Wendover, Paula Hilton, Allen Lising|
|Bronze||Current and Future Payment of Cell and Gene Therapies||Diane T. Smith, PhD, Ana Stojanovska, Matthew Sarnes, PharmD, Amanda O'Hora|
|Trends in the Uptake and Impact of the Institute for Clinical and Economic Review Value Assessment Framework in Payer Coverage Decisions From 2016 to 2020||Minha Choi, PharmD, MS; Tasmina Hydery, PharmD, MBA, BCGP; Robin Tan, PhD; Linnea Tennant, PharmD, MS, MBA|
|An Update on the Budget Impact of Appropriate Low-Dose Aspirin Utilization for Primary and Secondary Cardiovascular Event Prevention in the Managed Care Setting||Rashad Carlton, Barb Lennert and Annie Yan|
|Impact of the COVID-19 Pandemic on the Uptake of Telehealth Services: A Survey of US Payers||Chris Yost, Michael Sporck, Derek Louie, Melissa McCart|
|Current and Anticipated Digital Therapeutics Payer Perspectives in the COVID-19 Era||Annie Chang, Alex Kilgore, Song Lee, Ben Parcher, Barbara Carpenter, and Tim Frank|